Actelion Planning Tracleer Morbidity/Mortality Study In Idiopathic Pulmonary Fibrosis
This article was originally published in The Pink Sheet Daily
BUILD studies fail to show effect of bosentan on primary endpoints of exercise improvement, but positive morbidity/mortality trends were seen in idiopathic pulmonary fibrosis patients.
You may also be interested in...
Reports of hepatotoxicity are included in boxed warning for Actelion’s pulmonary arterial hypertension therapy.
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications